Proteomics Drug Discovery

One of the most promising developments to come from the study of human genes and proteins has been the identification of potential new drugs for the treatment of disease. This relies on genome and proteome information to identify proteins associated with a disease, which computer software can then use as targets for new drugs. For example, if a certain protein is implicated in a disease, the 3D structure of that protein provides the information a computer programs needs to design drugs to interfere with the action of the protein.The global proteomics market is projected to reach USD 21.87 Billion by 2021, at a CAGR of 11.7% from 2016 to 2021.

A molecule that fits the active site of an enzyme, but cannot be released by the enzyme, will inactivate the enzyme. This is the basis of new drug-discovery tools, which aim to find new drugs to inactivate proteins involved in disease. As genetic differences among individuals are found, researchers will use these same techniques to develop personalized drugs that are more effective for the individual.

  • Emerging trends in proteomics
  • Bioinformatics for proteomics
  • Practical applications of proteomics
  • Current research methodologies in Proteomics
  • Strutural proteomics.
  • Protein chips.
  • Proteogenomics.

Related Conference of Proteomics Drug Discovery

June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Baltimore, Maryland, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Proteomics Drug Discovery Conference Speakers

Recommended Sessions

Related Journals

Are you interested in